These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34712825)

  • 1. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma.
    Rehman O; Jaferi U; Padda I; Khehra N; Atwal H; Mossabeh D; Bhangu R
    Clin Exp Hepatol; 2021 Sep; 7(3):249-257. PubMed ID: 34712825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
    Kim JJ; McFarlane T; Tully S; Wong WWL
    Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
    Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.
    Alqahtani SA; Colombo MG
    World J Gastrointest Oncol; 2021 Dec; 13(12):2038-2049. PubMed ID: 35070040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.
    Personeni N; Pressiani T; Rimassa L
    J Hepatocell Carcinoma; 2019; 6():31-39. PubMed ID: 30775342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
    Sho T; Suda G; Ogawa K; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Baba M; Ito J; Yamamoto Y; Kobayashi T; Meguro T; Saga A; Miyagishima T; Terasita K; Takagi T; Kamiyama T; Taketomi A; Sakamoto N
    Hepatol Res; 2020 Aug; 50(8):966-977. PubMed ID: 32562334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
    J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
    Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center.
    Cosma LS; Weigand K; Müller-Schilling M; Kandulski A
    J Gastrointestin Liver Dis; 2021 Jun; 30(2):247-253. PubMed ID: 33951122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study.
    Palmer ME; Gile JJ; Storandt MH; Jin Z; Zemla TJ; Tran NH; Mahipal A
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
    Lee SW; Yang SS; Lien HC; Peng YC; Ko CW; Lee TY
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.
    Maruta S; Ogasawara S; Ooka Y; Obu M; Inoue M; Itokawa N; Haga Y; Seki A; Okabe S; Azemoto R; Itobayashi E; Atsukawa M; Sugiura N; Mizumoto H; Koroki K; Kanayama K; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Suzuki E; Nakamoto S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
    Liver Cancer; 2020 Aug; 9(4):382-396. PubMed ID: 32999866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
    Ichida A; Arita J; Hatano E; Eguchi S; Saiura A; Nagano H; Shindoh J; Hashimoto M; Takemura N; Taura K; Sakamoto Y; Takahashi Y; Seyama Y; Sasaki Y; Uemura K; Kokudo N; Hasegawa K
    Liver Cancer; 2024 Jun; 13(3):322-334. PubMed ID: 38894811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
    Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
    Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
    Tajiri K; Tokimitsu Y; Kawai K; Motofuji Y; Shinno E; Kashii Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
    Anticancer Res; 2022 Dec; 42(12):6007-6018. PubMed ID: 36456142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
    Sho T; Morikawa K; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Kimura M; Nakai M; Suda G; Natsuizaka M; Ogawa K; Sakamoto N
    World J Gastrointest Oncol; 2021 Dec; 13(12):2076-2087. PubMed ID: 35070043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.